ZVRA

Business Context and Reporting Period

Company: Zevra Therapeutics, Inc. (ZVRA)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Zevra is a commercial-stage biopharmaceutical company focused on rare diseases. Its primary commercial assets are MIPLYFFA (arimoclomol) for Niemann-Pick disease type C (NPC) and OLPRUVA (sodium phenylbutyrate) for urea cycle disorders (UCDs). The company is also advancing celiprolol for Vascular Ehlers-Danlos syndrome (VEDS) in Phase 3 trials.

Key Financial Metrics

Note: Q1 2025 comparative balance sheet data was not explicitly provided in the text, though Q1 2025 income statement data is available.

Material Changes vs. Prior Period

• Profitability Shift: The company reported a net income of $37.9 million in Q1 2026, a reversal from a net loss of $3.1 million in Q1 2025. This was primarily driven by a one-time gain on the sale of assets.
• Asset Sale (Commave Settlement): Zevra entered into a settlement agreement with Commave Therapeutics to sell its SDX portfolio (including AZSTARYS) and resolve litigation. This resulted in a $43.3 million gain on the sale of future royalties and intellectual property.
• Debt Extinguishment: Zevra repaid its entire $60 million term loan facility in March 2026. This incurred a $2.8 million loss on extinguishment of debt and a $7.2 million loss on derivative liability related to the embedded derivative in the credit agreement.
• Revenue Growth: Net revenue increased by $15.8 million (78% increase) year-over-year, driven by higher sales of MIPLYFFA ($24.6M vs $17.1M) and increased revenue from the global Expanded Access Program ($10.2M vs $2.3M).
• Intangible Amortization: Amortization expense decreased significantly to $0.3 million from $1.6 million due to the full impairment of OLPRUVA-related intangible assets in Q2 2025.

Guidance, Outlook, and Risks

• Liquidity: As of March 31, 2026, the company held $236.8 million in cash, cash equivalents, and investments. Management believes this is sufficient to fund operations for at least the next 12 months.
• Commercial Outlook:
  • MIPLYFFA: Commercialization continues in the U.S. with 170 enrollments as of March 31, 2026. An MAA for the EU was filed in July 2025 and is under review.
  • OLPRUVA: The company is scaling back sales and marketing efforts and evaluating strategic alternatives due to limited commercial success.
  • Celiprolol: The Phase 3 DiSCOVER trial for VEDS has 62 enrolled participants as of March 31, 2026. The company is engaging with the FDA to discuss regulatory options to accelerate development.
• Risks and Contingencies:
  • Regulatory & Pricing: Risks include potential impacts from the "One Big Beautiful Bill Act" (July 2025) on Medicaid funding and proposed U.S. tariffs on pharmaceuticals (effective July 31, 2026), though MIPLYFFA may be exempt due to orphan status.
  • Legal: The pending litigation with Commave regarding the AZSTARYS License Agreement was resolved in March 2026 via the settlement agreement.
  • Capital Needs: While currently liquid, the company notes it has a history of negative operating cash flows and may need to raise additional capital through equity or debt, which could result in dilution.

Investor Verification Checklist

• Sustainability of Earnings: Verify the extent to which the Q1 2026 net income is driven by the non-recurring $43.3 million asset sale gain versus organic product revenue growth.
• Debt-Free Status: Confirm the complete removal of the $60 million term loan and associated covenants from the balance sheet.
• OLPRUVA Strategy: Monitor announcements regarding the "strategic alternatives" for OLPRUVA, as the company is actively scaling back commercial efforts.
• Celiprolol Trial Progress: Track enrollment rates for the Phase 3 DiSCOVER trial (currently 62 of 150 targeted) and upcoming FDA meeting outcomes.
• Regulatory Exposure: Assess the potential financial impact of the new "One Big Beautiful Bill Act" and proposed tariffs on future reimbursement rates and manufacturing costs.